Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity

Journal of Virology(2021)10.1128/jvi.02350-20Source: DataRank Database

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity is a research paper published in Journal of Virology (2021). On theSindex it has a DataRank of 0.584. It has been cited 14 times, with 5 citing works in its 1-hop citation network.

N/A

0.584DataRank · unranked

Scored on demand from live citation data

Open Access14 citations · 5 citing works in its network

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.51)OA: hybridTopics (68)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 70%Citation Network 30%

Base Score Contribution

0.406

From this paper's citation signal

Citation Network Contribution

0.178

From 4 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 5 citers.

A new lease on life for an HIV-neutralizing antibody class and vaccine target
Proceedings of the National Academy of Sciences20217 citations22 referencesContributes 0.095
Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses
bioRxiv (Cold Spring Harbor Laboratory)202137 citations62 referencesContributes 0.059
A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies
International Journal of Molecular Sciences20232 citations33 referencesContributes 0.033
Current drugs for HIV-1: from challenges to potential in HIV/AIDS
Frontiers in Pharmacology202329 citations149 referencesContributes 0.023
Biotechnology Advances in Disease Treatment
Elsevier eBooks20240 citations231 referencesContributes 0.000

Authors (8)

Maria V. Filsinger Interrante ORCID,Benjamin N. Bell ORCID,Clayton L. Brown,Theodora U. J. Bruun ORCID,Celia C. LaBranche ORCID

Live enrichment

PubMed:33980592 PMC:PMC8274607 OpenAlex:https://openalex.org/W3162941534

HHS | National Institutes of Health

Grant: DP1DA043893

HHS | National Institutes of Health

Grant: HHSN272201800004C

HHS | National Institutes of Health

Grant: T32GM007276

HHS | National Institutes of Health

Grant: T32GM007365

National Institutes of Health

Grant: 5T32GM007365-23

MEDICAL SCIENTIST TRAINING PROGRAM

National Institutes of Health

Grant: 5T32GM007276-36

Cellular and Molecular Biology Training Program

National Institutes of Health

Grant: 5DP1DA043893-02

Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery

FWCI

1.51

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

hybridLicense: cc-by

journalhttps://doi.org/10.1128/jvi.02350-20

publisherhttps://doi.org/10.1128/jvi.02350-20

publisherhttps://journals.asm.org/doi/pdf/10.1128/JVI.02350-20

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33980592

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8274607

Fields of Study

HIV Research and TreatmentImmune Cell Function and InteractionHIV/AIDS drug development and treatment0301 basic medicine0303 health sciences03 medical and health sciencesAnti-HIV AgentsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCell LineEnfuvirtideHEK293 CellsHIV Envelope Protein gp41HIV InfectionsHIV-1HumansProtein Domains

MeSH Terms

Protein DomainsEnfuvirtideAntibodies, MonoclonalAntibodies, ViralCell LineHumansHIV-1HIV InfectionsHIV Envelope Protein gp41Anti-HIV AgentsAntibodies, NeutralizingHEK293 Cells

Keywords

Gp41NeutralizationVirologyAntibodyMonoclonal antibodyBiologyNeutralizing antibodyHeptad repeatEnfuvirtideHIV vaccinePotencyFragment crystallizable regionGlycoproteinLentivirusMolecular biologyEpitopeHuman immunodeficiency virus (HIV)VirusPeptide sequenceVaccine trialImmunologyGeneIn vitroGeneticsHIV-1AntibodiesPrehairpin IntermediateAnti-HIV AgentsAntibodies, MonoclonalHIV InfectionsAntibodies, ViralAntibodies, NeutralizingHIV Envelope Protein gp41Cell LineHEK293 CellsProtein DomainsVaccines and Antiviral AgentsHumans

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Related Papers (2)

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

N/A

11.1DataRank · unranked

Nature Medicine(2020)

co-cited

10.1038/s41591-020-0998-x

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

N/A

12.9DataRank · unranked

Cell Reports(2020)

co-cited

10.1016/j.celrep.2020.107725

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (8)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)

Related Papers (2)